2-benzyl-3-[(benzyloxycarbonyl)amino]propanoic acid | 120686-14-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-benzyl-3-[(benzyloxycarbonyl)amino]propanoic acid
• 英文别名: N-Cbz-3-amino-2-benzyl propionic acid；2-(phenylmethyl)-3-[[(phenylmethoxy)carbonyl]-amino]propionic acid；N-benzyloxycarbonyl-3-amino-2-benzylpropionic acid；2-benzyl-3-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 120686-14-8
• 化学式: C₁₈H₁₉NO₄
• 分子量: 313.353
• InChiKey: FCMHQDUEDVBCNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-benzyl-3-[(benzyloxycarbonyl)amino]propanoic acid 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 苯 为溶剂， 反应 5.5h， 生成 2(RS)-Benzyl-β-alanine tert-butyl ester
  参考文献：
  名称：

  New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties

  摘要：

  In order to improve the in vivo protection of enkephalins from enzymatic degradation, a new series of inhibitors derived from kelatorphan [HONHCOCH2CH(CH2Ph)CONHCH(CH3)COOH], the first-described complete inhibitor of enkephalin metabolism, were designed by modification of the C-terminal amino acid. The progressive lengthening of the chain of this residue shows that a beta-alanine seems to be the best basic model for the conception of such types of compounds. On the other hand, the methylation of the amide bond, which is well accepted by aminopeptidase N (EC 3.4.11.2) and dipeptidylaminopeptidase, induced a significant loss of affinity for neutral endopeptidase -24.11. Starting from these data, compounds containing a variously substituted beta-alanine residue and corresponding to the general formula HONHCOCH2CH(CH2Ph)CONHCH(R1)CH(R2)COOH were synthesized. All these molecules inhibit neutral endopeptidase -24.11 and dipeptidylaminopeptidase in the nanomolar range, and those containing an aromatic chain (compound 7A, R1 = CH2Ph,R2 = H, and compound 8A, R1 = Ph, R2 = H) inhibit the biologically relevant aminopeptidase N, with IC50's around 10(-8) M. Intracerebroventricular injection in mice of these multienzyme inhibitors produced an efficient and naloxone-reversible analgesic response (hot plate test): compounds 7A and 8A were shown to be more potent than kelatorphan in increasing the jump latency time, in agreement with their in vitro properties, and these new compounds were found to increase the forepaw lick latency, a reflex considered as a typical morphine response.

  DOI：

  10.1021/jm00127a017
• 作为产物：
  描述：

  2-苄基丙烯酸 在 盐酸羟胺 、 sodium ethanolate 作用下， 以 乙醇 为溶剂， 以25.4%的产率得到2-benzyl-3-[(benzyloxycarbonyl)amino]propanoic acid
  参考文献：
  名称：

  New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties

  摘要：

  In order to improve the in vivo protection of enkephalins from enzymatic degradation, a new series of inhibitors derived from kelatorphan [HONHCOCH2CH(CH2Ph)CONHCH(CH3)COOH], the first-described complete inhibitor of enkephalin metabolism, were designed by modification of the C-terminal amino acid. The progressive lengthening of the chain of this residue shows that a beta-alanine seems to be the best basic model for the conception of such types of compounds. On the other hand, the methylation of the amide bond, which is well accepted by aminopeptidase N (EC 3.4.11.2) and dipeptidylaminopeptidase, induced a significant loss of affinity for neutral endopeptidase -24.11. Starting from these data, compounds containing a variously substituted beta-alanine residue and corresponding to the general formula HONHCOCH2CH(CH2Ph)CONHCH(R1)CH(R2)COOH were synthesized. All these molecules inhibit neutral endopeptidase -24.11 and dipeptidylaminopeptidase in the nanomolar range, and those containing an aromatic chain (compound 7A, R1 = CH2Ph,R2 = H, and compound 8A, R1 = Ph, R2 = H) inhibit the biologically relevant aminopeptidase N, with IC50's around 10(-8) M. Intracerebroventricular injection in mice of these multienzyme inhibitors produced an efficient and naloxone-reversible analgesic response (hot plate test): compounds 7A and 8A were shown to be more potent than kelatorphan in increasing the jump latency time, in agreement with their in vitro properties, and these new compounds were found to increase the forepaw lick latency, a reflex considered as a typical morphine response.

  DOI：

  10.1021/jm00127a017

文献信息

• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• Antithrombotic agents
  申请人：Eli Lilly and Company

  公开号：US05488037A1

  公开（公告）日：1996-01-30

  This invention relates to L-Arginine aldehyde derivatives, pharmaceutical formulations containing those compounds and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.

  这项发明涉及L-精氨酸醛衍生物，含有这些化合物的药物配方以及它们作为凝血酶抑制剂、凝血抑制剂和血栓性疾病药剂使用的方法。
• Bisulfite adducts of arginine aldehydes
  申请人：Eli Lilly and Company

  公开号：US05436229A1

  公开（公告）日：1995-07-25

  This invention relates to bisulfite adducts of L-Arginine aldehyde derivatives, pharmaceutical formulations containing those adducts and methods of their use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents.

  这项发明涉及L-精氨酸醛衍生物的亚硫酸氢盐加合物，含有这些加合物的药物配方以及其作为凝血酶抑制剂、凝血抑制剂和血栓栓塞性疾病药物的使用方法。
• 7-MEMBERED RING COMPOUND AND METHOD OF PRODUCTION AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：Muto Tsuyoshi

  公开号：US20090253683A1

  公开（公告）日：2009-10-08

  A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.

  本发明提供一种具有式(I)的7元杂环化合物或其盐或其溶剂合物，具有抑制chymase的作用，用于预防或治疗各种涉及chymase的疾病的方法，以及用于预防或治疗各种涉及chymase的疾病的药物组合物，包括具有式(I)的化合物或其药学上可接受的盐或其溶剂合物的药物组合物。
• 7-membered ring compound and method of production and pharmaceutical application thereof
  申请人：Muto Tsuyoshi

  公开号：US20090111796A1

  公开（公告）日：2009-04-30

  A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.

  提供了一种具有以下公式（I）或其盐或溶剂化物的七元杂环化合物，具有抑制chymase作用，可用于预防或治疗各种涉及chymase的疾病的方法，以及用于预防或治疗这些疾病的制药组合物，包括具有以下公式（I）或其药学上可接受的盐或溶剂化物的化合物。